MDI-1228_mesylate / Shanghai Medinno - LARVOL DELTA

DFU: The Purpose of This Study is to Evaluate the Efficacy and the Safety of MDI-1228 Mesylate Gel Compared With Standard of Care Alone in Patients With Chronic Diabetic Foot Ulcers (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.

New P2 trial

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Shanghai Medinno Pharmaceutical Technology Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ May 2024

Trial completion • Trial completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults and Participants With Allergic Conjunctivitis (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Shanghai Medinno Pharmaceutical Technology Co., Ltd.

Trial completion date • Trial primary completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults and Participants With Allergic Conjunctivitis (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Shanghai Medinno Pharmaceutical Technology Co., Ltd.

New P1 trial • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology